Early research suggests psilocybin can reduce chronic pain, with some studies showing relief that lasts days to weeks after a single dose. The evidence is still limited to small trials, animal studies, and surveys, but the results so far are promising enough that multiple clinical trials are now underway.
How Psilocybin Affects Pain Signaling
Psilocybin is inactive on its own. Your body quickly converts it into psilocin, which binds to serotonin receptors throughout the brain and spinal cord. The receptor most responsible for its pain-relieving effects is the same one that produces its psychedelic properties: the 5-HT2A receptor. In mouse models of chronic pain, blocking this receptor eliminated psilocybin’s analgesic effects entirely, confirming it as the primary pathway.
Chronic pain physically changes the brain. A 2025 study in Nature Neuroscience found that in mice with chronic pain, neurons in the anterior cingulate cortex (a brain region involved in processing both pain and emotion) become hyperactive. A single dose of psilocin rapidly normalized that hyperactivity and reversed both pain sensitivity and depression-like behavior. Injecting psilocin directly into this brain region reproduced the effect, pointing to it as a critical site of action. This is notable because chronic pain and depression frequently co-occur, and psilocybin appears to address both through the same neural circuits.
There may also be an inflammatory component. Lab research on immune cells found that psilocin reduced levels of TNF-alpha, a key inflammatory molecule, in activated macrophages. It also boosted production of IL-10, an anti-inflammatory signal. These effects were more pronounced when psilocin was applied after inflammation had already started, suggesting it could help calm an immune response already in progress. Psilocybin itself showed weaker anti-inflammatory effects than psilocin, which matters because psilocin is what actually circulates in your body after you take psilocybin.
What the Human Evidence Shows So Far
The strongest human data comes from surveys and small pilot trials rather than large randomized studies. A survey of 250 chronic pain sufferers who had used psychedelics found that full psychedelic doses (“macrodoses”) provided statistically greater pain relief than microdoses, opioids, cannabis, and over-the-counter painkillers. On a 0-to-10 scale, macrodoses scored an average pain relief rating of 8.23, compared to 7.12 for microdoses and 5.36 for conventional medications. Macrodoses also outperformed each drug class individually: they beat opioids, NSAIDs, and cannabis in head-to-head comparisons. Microdoses beat NSAIDs and cannabis but were not significantly better than opioids.
This is survey data, which carries real limitations. People who seek out psychedelics for pain relief may be predisposed to report positive results, and there’s no way to control for placebo effects. Still, the consistency of the pattern across different pain conditions and drug comparisons is noteworthy.
Fibromyalgia
A small open-label pilot trial tested psilocybin-assisted therapy in adults with fibromyalgia. One month after their second dose, participants showed a 2.3-point average decrease in pain severity on a 0-to-10 scale, with a very large effect size. Pain interference with daily life dropped by 9.4 points, and sleep disturbance improved even more dramatically, with a 7-point average decrease. Three of the five participants reported their symptoms “much improved” or “very much improved.” No serious adverse events occurred.
Headache Disorders
Cluster headaches and migraines have drawn particular interest. A systematic review found that macrodosing provided more headache pain relief than microdosing, with a 12.3% difference in the proportion of participants experiencing pain reduction three days after a dose. Some participants did report a temporary increase in pain and anxiety shortly after dosing: 5.3% with microdoses and 14.1% with macrodoses. This temporary worsening before improvement is a pattern clinicians are watching closely.
Phantom Limb Pain
One striking case report described a patient with intractable phantom limb pain who combined psilocybin with mirror visual feedback, a technique where watching the reflection of an intact limb tricks the brain into “seeing” the missing one. The combination completely eliminated phantom limb pain and reduced the frequency of sudden pain episodes. Neither treatment alone had achieved that level of relief.
Full Doses vs. Microdoses for Pain
The available evidence consistently favors full psychedelic doses over microdoses for pain relief, though microdoses aren’t useless. In the 250-person survey, macrodoses produced significantly greater reductions in pain intensity and greater increases in pain acceptance. The relief also lasted longer: one-third of macrodose users still felt benefits more than three days later, compared to about one-fifth of microdose users.
Microdosing had its own advantages. Users reported greater convenience, fewer side effects, and a perception of safety since they could maintain normal daily functioning. For people who can’t take time for a full psychedelic experience or who find the idea of a hallucinogenic session uncomfortable, microdosing may still offer meaningful, if more modest, benefits.
How Psilocybin Changes the Experience of Pain
Pain isn’t purely a physical signal. How you think about and relate to your pain shapes how much it disrupts your life. Psilocybin appears to work on this psychological dimension as well. People who have used psychedelics for chronic pain frequently describe increased acceptance of their condition, a sense of empowerment, and renewed hope, effects that contrast sharply with the helplessness and catastrophizing that often accompany long-term pain.
Researchers believe this happens because psilocybin increases neural flexibility, essentially loosening rigid patterns of thought and allowing people to reappraise their relationship with pain. A Phase Ib study on a type of neuralgiform headache highlighted that psychological insight and shifts in pain perception were central to the therapeutic effect, not just the pharmacological action of the drug itself. This is why most clinical protocols pair psilocybin with psychotherapy sessions before, during, and after dosing.
Safety Profile in Pain Populations
Across all clinical studies conducted to date, adverse events have been few or absent, and those that did occur were mild and transient, never requiring anyone to stop treatment. Psilocybin shows low potential for physical dependence compared to opioids and most other pain medications.
That said, psilocybin produces intense psychological experiences that can be destabilizing for certain people. Rare but serious complications include seizures, psychotic episodes, panic attacks, and mood instability. Current trials screen out people with a history of psychosis, seizure disorders, or severe mood instability. Individual differences in genetics, brain chemistry, and mental health history all influence how someone responds, which is why researchers emphasize the need for personalized treatment plans and controlled clinical settings.
Where Things Stand Legally and Clinically
Psilocybin remains a Schedule I controlled substance in the United States, meaning it has no approved medical use under federal law. The FDA has issued draft guidance for conducting clinical trials with psychedelic drugs, acknowledging the growing interest in their therapeutic potential, but no psilocybin-based pain treatment has received FDA approval or breakthrough therapy designation for pain specifically.
Several trials are actively recruiting. A double-blind, placebo-controlled trial at the University of Alabama at Birmingham is testing psilocybin for chronic pain using a dose of 0.36 mg per kilogram of body weight, with 30 participants and daily pain severity as the primary outcome. Results from trials like these will determine whether psilocybin moves toward clinical availability for pain conditions. Until that data arrives, the current evidence is encouraging but preliminary, built on small samples and early-stage research that needs replication at scale.